SPOTLIGHT: GSK signing new vaccine deals
Fresh from signing a deal to supply Switzerland and Singapore with enough avian flu vaccine to inoculate the country's entire population, GlaxoSmithKline is now in talks to sign similar deals with France and the U.K. The vaccine has not yet been approved, but the EMEA's stamp of approval is expected in a matter of weeks. Some concerns have been raised that the new vaccine may not be effective against any new strain of avian flu that may trigger a human pandemic. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
